Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors

Hambach, Julia; Mann, Anna Marei; Bannas, Peter; Koch‐Nolte, Friedrich

doi:10.3389/fimmu.2022.1005800

Cited by 4 publications

(1 citation statement)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although in the early stages of development, these compounds are showing promising pre-clinical and clinical results. [26,27] Given that they are highly potent, they may indeed benefit from the low-dose, sustained-release profile observed with MAPs. In this case, painless administration using MAPs could certainly gain greater acceptance among patients.…”

Section: Discussionmentioning

confidence: 99%

Transdermal Administration of Nanobody Molecules using Hydrogel‐Forming Microarray Patch Technology: A Unique Delivery Approach

Hutton,

Kirkby,

Van Bogaert

et al. 2024

Macro Materials & Eng

View full text Add to dashboard Cite

Nanobody molecules, derived from heavy‐chain only antibodies in camelids, represent the next generation of biotherapeutics. In addition to low immunogenicity, high stability, and potency, their single‐domain format facilitates the construction of multivalent molecules for therapeutic applications. Although predominantly administered using a hypodermic syringe and needle, alternative delivery methods are under investigation. That said, the transdermal route has yet to be explored. Therefore, microarray patch (MAP) technology, offering a potentially high dose, pain‐free transdermal system, is employed in this study. Trivalent Nanobody molecules, with and without half‐life extension (VHH and VHH[HLE]), are formulated into hydrogel‐forming MAPs, with pharmacokinetic parameters assessed in Sprague–Dawley rats. VHH MAPs exhibited a sustained release profile, with a serum concentration of 19 ± 9 ng mL−1 24 h post‐administration. In contrast, a subcutaneous (SC) injection showed faster clearance, with a serum concentration of 1.1 ± 0.4 ng mL−1 at 24 h. For VHH(HLE), both SC and MAP cohorts achieved a maximum serum concentration (Tmax) at 24 h. The MAP cohort displayed a notable increase in VHH(HLE) serum levels between 6–24 h, dropping after MAP removal. This study has exemplified MAPs potential for delivering advanced biologics, indicating the transdermal route's promise for pain‐free, patient‐friendly administration of Nanobody molecules.

show abstract

Section: Discussionmentioning

confidence: 99%

Transdermal Administration of Nanobody Molecules using Hydrogel‐Forming Microarray Patch Technology: A Unique Delivery Approach

Hutton,

Kirkby,

Van Bogaert

et al. 2024

Macro Materials & Eng

View full text Add to dashboard Cite

show abstract

Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors

Gu,

Zhao

2024

Mol Diagn Ther

View full text Add to dashboard Cite

In recent years, bispecific antibodies (BsAbs) have emerged as a promising therapeutic strategy against tumors. BsAbs can recruit and activate immune cells, block multiple signaling pathways, and deliver therapeutic payloads directly to tumor sites. This review provides a comprehensive overview of the recent advances in the development and clinical application of BsAbs for the treatment of solid tumors. We discuss the different formats, the unique mechanisms of action, and the clinical outcomes of the most advanced BsAbs in solid tumor therapy. Several studies have also analyzed the clinical progress of bispecific antibodies. However, this review distinguishes itself by exploring the challenges associated with bispecific antibodies and proposing potential solutions. As the field progresses, BsAbs hold promise to redefine cancer treatment paradigms and offer new hope to patients with solid tumors.

show abstract

Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells

Giang,

Boxaspen,

Diao

et al. 2023

New Biotechnology

View full text Add to dashboard Cite

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors

Cited by 4 publications

References 107 publications

Transdermal Administration of Nanobody Molecules using Hydrogel‐Forming Microarray Patch Technology: A Unique Delivery Approach

Transdermal Administration of Nanobody Molecules using Hydrogel‐Forming Microarray Patch Technology: A Unique Delivery Approach

Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors

Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells

Contact Info

Product

Resources

About